• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ONDANSETRON Drug Record

  • Summary
  • Interactions
  • Claims
  • ONDANSETRON chembl:CHEMBL46 Approved

    Alternate Names:

    ZOFRAN
    ZUPLENZ
    A04AA01
    GR-38032
    ONDANSETRON
    EUR-1025
    ZOFRAN ODT
    DESMETHYLONDANSETRON
    GR-38032F

    Drug Info:

    Drug Indications for treatment of obsessive compulsive disorder (OCD)
    FDA Approval approved
    Drug Indications antiemetic
    FDA Approval not approved
    Drug Class Small Molecule
    Drug Indications for treatment of sleep apnea
    Year of Approval 1991
    Drug Class antiemetics
    (4 More Sources)

    Publications:

    Carvalho et al., 2002, Central 5-HT3 receptor stimulation by m-CPBG increases blood glucose in rats., Horm. Metab. Res.
    Gallardo Lara et al., 2009, Ondansetron: design and development of oral pharmaceutical suspensions., Pharmazie
    Arcioni et al., 2002, Ondansetron inhibits the analgesic effects of tramadol: a possible 5-HT(3) spinal receptor involvement in acute pain in humans., Anesth. Analg.
    Ramsook et al., 2002, A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis., Ann Emerg Med
    Artaiz et al., 1998, Characterization of serotonergic mechanisms involved in the behavioural inhibition induced by 5-hydroxytryptophan in a modified light-dark test in mice., Behav Pharmacol
    Gregory et al., 1998, 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy., Drugs
    Szajewska et al., 2007, Meta-analysis: ondansetron for vomiting in acute gastroenteritis in children., Aliment. Pharmacol. Ther.
    Dimitrov, 2009, Effect of Ondansetron, a 5-HT(3) receptor antagonist, on fatigue in 2 veterans with hepatitis C., Prim Care Companion J Clin Psychiatry
    Fortuño et al., 1999, CCK-mediated response in the activation of 5-HT receptor types in the guinea-pig ileum., J. Physiol. Biochem.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Mohan et al., 1995, Ondansetron hydrochloride: a competitive serotonin 5-HT3 receptor blocker., Acta Crystallogr C
    Gan, 2005, Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same?, CNS Drugs
    Llácer et al., 2001, X-ray diffraction and electron microscopy in the polymorphism study of ondansetron hydrochloride., Drug Dev Ind Pharm
    Kasho et al., 1998, Serotonin enhances the production of type IV collagen by human mesangial cells., Kidney Int.
    He H et al., 2014, Association of ABCB1 polymorphisms with the efficacy of ondansetron in chemotherapy-induced nausea and vomiting., Clin Ther
    Choi EM et al., 2010, Association of ABCB1 polymorphisms with the efficacy of ondansetron for postoperative nausea and vomiting., Anaesthesia
    Johnson BA et al., 2011, Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking., Am J Psychiatry
    Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
    Stamer UM et al., 2011, CYP2D6- and CYP3A-dependent enantioselective plasma concentrations of ondansetron in postanesthesia care., Anesth Analg
    Netzer et al., 2002, Does intravenous ondansetron affect gastric emptying of a solid meal, gastric electrical activity or blood hormone levels in healthy volunteers?, Aliment. Pharmacol. Ther.
    Ozmen et al., 2004, Effects of antiemetic drugs on glucose 6-phosphate dehydrogenase and some antioxidant enzymes., Pharmacol. Res.
  • ONDANSETRON   PPY

    Interaction Score: 4.58

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11856086


    Sources:
    NCI

  • ONDANSETRON   HTR3A

    Interaction Score: 2.65

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Serotonin 3a (5-HT3a) receptor antagonist
    Trial Name BGC20-0166

    PMIDs:
    11972287 19320280 12032025 11919526 10065930 9506240 17269994 20098535 10517265 11752352 8588861 15740177 11763467


    Sources:
    TdgClinicalTrial ChemblInteractions TEND TTD

  • ONDANSETRON   GSR

    Interaction Score: 0.92

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15458770


    Sources:
    NCI

  • ONDANSETRON   SLC6A4

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21247998


    Sources:
    PharmGKB

  • ONDANSETRON   HTR2A

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9767524


    Sources:
    NCI

  • ONDANSETRON   CYP3A5

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21596874


    Sources:
    PharmGKB

  • ONDANSETRON   ABCB1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25012726 20707787


    Sources:
    PharmGKB

  • ONDANSETRON   CYP3A4

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9187528


    Sources:
    PharmGKB

  • ONDANSETRON   CYP2D6

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    FDA

  • TEND: ONDANSETRON

    • Version: 01-August-2011

    Alternate Names:
    ONDANSETRON Primary Drug Name

    Drug Info:
    Drug Class antiemetics
    Year of Approval 1991

    Publications:

  • TdgClinicalTrial: ONDANSETRON

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications for treatment of sleep apnea
    Drug Class Small Molecule
    FDA Approval not approved

    Publications:

  • NCI: ONDANSETRON

    • Version: 14-September-2017

    Alternate Names:
    C1119 NCI drug code

    Drug Info:

    Publications:
    Netzer et al., 2002, Does intravenous ondansetron affect gastric emptying of a solid meal, gastric electrical activity or blood hormone levels in healthy volunteers?, Aliment. Pharmacol. Ther.
    Ozmen et al., 2004, Effects of antiemetic drugs on glucose 6-phosphate dehydrogenase and some antioxidant enzymes., Pharmacol. Res.
    Kasho et al., 1998, Serotonin enhances the production of type IV collagen by human mesangial cells., Kidney Int.

  • PharmGKB: ondansetron

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    He H et al., 2014, Association of ABCB1 polymorphisms with the efficacy of ondansetron in chemotherapy-induced nausea and vomiting., Clin Ther
    Choi EM et al., 2010, Association of ABCB1 polymorphisms with the efficacy of ondansetron for postoperative nausea and vomiting., Anaesthesia
    Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev

  • TTD: Ondansetron

    • Version: 2020.06.01

    Alternate Names:
    D0K7WK TTD Drug ID

    Drug Info:

    Publications:

  • FDA: Ondansetron

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL46

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL46

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21